Author

RW Klein

Institution: Medical Decision Modeling (United States)

Observed institution: Medical Decision Modeling (United States)

OpenAlex ID: A5109099927

Belimumab for the Treatment of Adults Living with Active Systemic Lupus Erythematosus: A Cost-Effectiveness Analysis in Canada

2018 · S Mursleen, JC Gahn, et al. · Value in Health · 2

Pmh21 Cost-effectiveness of Olanzapine Long-acting Injection in the Treatment of Non-adherence Patients With Schizophrenia in the United States

2009 · H Ascher-Svanum, NM Furiak, et al. · Value in Health · 2

Budget Impact Analysis of Basaglar for the Treatment of Type 1 and Type 2 Diabetes in Patients Eligible for a Long-Acting Insulin Analog

2018 · CA Bly, JC Gahn, et al. · Value in Health · 1

Pmc15 Synchronization of Random Number Streams Greatly Enhances Efficiency of Probabilistic Models

2010 · LJ Smolen, RW Klein · Value in Health · 1

Evaluating The Addition To Formulary of Belimumab For The Treatment of Systemic Lupus Erythematosus: A Cost-Effectiveness Model

2017 · KA Kelton, JC Gahn, et al. · Value in Health

Cost-Effectiveness of Solifenacin for The Treatment of Overactive Bladder From A Us Private Payer and Medicare Advantage Perspective

2016 · DB Ng, R Wielage, et al. · Value in Health

Pdb33 Evaluation of Cost and Clinical Outcomes by Hba1c at Diagnosis Using Various Diabetes Treatment Strategies

2010 · LJ Lee, RW Klein, et al. · Value in Health

Pcn20 the Budgetary Impact of Pemetrexed Plus Cisplatin as First-line Therapy for Advanced Nonsquamous Non-small Cell Lung Cancer (nsclc)

2009 · RC Wielage, CE Muehlenbein, et al. · Value in Health

Pmc30 Using an Encounter-based Database to Validate a Disease Progression Model: Lessons for Modelers

2009 · TM Klein, RC Wielage, et al. · Value in Health

Pmh35 Cost-effectiveness of Orally Dissolving Olanzapine Tablets in the Treatment of Schizophrenia in the Usa

2008 · H Ascher-Svanum, NM Furiak, et al. · Value in Health

Pmh23 Cost-effectiveness of Olanzapine Versus Generic Risperidone and Other Antipsychotics in Standard Oral Formulations in Patients With Schizophrenia in the Us

2007 · H Ascher-Svanum, NM Furiak, et al. · Value in Health

Pcv64 Factor Screening for Parsimony of Variables in Pharmacoeconomic Models

2007 · RW Klein, R Yaesoubi, et al. · Value in Health

Pg18 a Cost-effectiveness Analysis of Screening for Esophageal Varices: How Good Does a Clinical Decision Aid Have to Be?

2006 · RW Klein, TF Imperiale, et al. · Value in Health

Pcv5 Potential Cost Savings From Acute Coronary Syndrome Treatment Improvements

2005 · RW Klein, RL Ohsfeldt, et al. · Value in Health

Pcv28 an Arb Cost-effectiveness Model in Treating Mild-to-moderate Hypertension

2004 · HJ Smolen, RW Klein, et al. · Value in Health

Works count: 15

Citation count: 6

H-index: 2

I10-index: